Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
709 (USA) · Dr. Novak
consented 2013-07-19
AEs
1
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild DIABETES MELLITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-08-30 (study day 43.0); relationship: NONE
Data queries
No data queries.